Biotech & Pharmaceuticals

Purdue Pharma, the maker of OxyContin, the drug widely seen connected to the opioid crisis, has its day in court. Meg Tirrell is at the courthouse for us at White Plains, New York.

Meg Tirrell reports on how Purdue Pharma files for bankruptcy but legal battles are still ahead.

Steve Miller, chairman of Purdue Pharma’s board of directors, told CNBC on Monday that the OxyContin maker’s bankruptcy and tentative deal to resolve opioid lawsuits was the “only way” to get help to victims of the crisis as quickly as possible.

Meg Tirrell reports on the pharmaceutical companies that are in the center of opioid settlement talks.

An Oklahoma judge finds that Johnson & Johnson helped fueled the state’s opioid crisis. Meg Tirrell has more for us from Norman, Oklahoma.

With the recent opioid ruling against Johnson & Johnson, how does this impact the rest of the pharmaceutical industry? Chris Meekins, a Healthcare Policy Analyst at Raymond James, gives us his insights.

Shares of drug distributors fell Tuesday after a report said McKesson, Cardinal Health and AmerisourceBergen have proposed paying $10 billion to settle claims they helped to fuel the U.S. opioid epidemic.

The Trump administration outlined on Wednesday a proposal that would allow the U.S. to legally import cheaper prescription drugs from Canada, a tactic the U.S. pharmaceutical industry and regulators have warned could threaten consumer safety.

Drug maker companies Merck and Eli Lilly posted better than expected results in its quarterly earnings reports. Meg Tirrell takes a closer look at both of these big pharmaceutical firms.

President Donald Trump is working on a proposal that would allow the United States to import drugs from Canada, Health and Human Services Secretary Alex Azar told CNBC.

Pfizer will be merging with its off patent business with Mylan creating a new company that controls a number of blockbuster medicines. Meg Tirrell has more for us on this mega deal.

Pfizer, the world’s largest drugmaker, plans to divest its off-patent drug business and combine it with generic-drug maker Mylan.

Senate Finance Committee Chairman Chuck Grassley said Thursday that he wants to include an abandoned White House proposal that would have eliminated rebates from government drug plans in the final version of a bipartisan drug pricing bill.

Meg Tirrell reports on one drug company’s strategy to combat itself from possible liabilities of its oxycodone and hydrocodone pills

Just over a year after buying online pharmacy PillPack for $753 million, Amazon is engaged in a bitter battle with an incumbent player in the pharmacy industry, which sources tell CNBC is working behind the scenes to prevent the company from accessing important patient data.